The landscape of oncology is characterized by rapid, often disruptive trends, particularly in the rare disease space. One of the most significant shifts is the move towards tissue-agnostic approvals. Traditionally, a cancer drug was approved for a specific organ site (e.g., lung cancer, colon cancer). However, the discovery of common molecular drivers, such as the NGR1 fusion, across...